In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy
Open Access
- 1 January 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Annals of Clinical Microbiology and Antimicrobials
- Vol. 7 (1), 4
- https://doi.org/10.1186/1476-0711-7-4
Abstract
In a recent multi-centre Italian survey (2003–2004), conducted in 45 laboratories throughout Italy with the aim of monitoring microorganisms responsible for severe infections and their antibiotic resistance, Acinetobacter baumannii was isolated from various wards of 9 hospitals as one of the most frequent pathogens. One hundred and seven clinically significant strains of A. baumannii isolates were included in this study to determine the in vitro activity of tigecycline and comparator agents. Tests for the susceptibility to antibiotics were performed by the broth microdilution method as recommended by CLSI guidelines. The following antibiotics were tested: aztreonam, piperacillin/tazobactam, ampicillin/sulbactam, ceftazidime, cefepime, imipenem, meropenem tetracycline, doxycycline, tigecycline, gentamicin, amikacin, ciprofloxacin, colistin, and trimethoprim/sulphametoxazole. The PCR assay was used to determine the presence of OXA, VIM, or IMP genes in the carbapenem resistant strains. A. baumannii showed widespread resistance to ceftazidime, ciprofloxacin and aztreonam in more than 90% of the strains; resistance to imipenem and meropenem was 50 and 59% respectively, amikacin and gentamicin were both active against about 30% of the strains and colistin about 99%, with only one strain resistant. By comparison with tetracyclines, tigecycline and doxycycline showed a higher activity. In particular, tigecycline showed a MIC90 value of 2 mg/L and our strains displayed a unimodal distribution of susceptibility being indistinctly active against carbapenem-susceptible and resistant strains, these latter possessed OXA-type variant enzymes. In conclusion, tigecycline had a good activity against the MDR A. baumannii strains while maintaining the same MIC90 of 2 mg/L against the carbapenem-resistant strains.Keywords
This publication has 47 references indexed in Scilit:
- Global Challenge of Multidrug-ResistantAcinetobacter baumanniiAntimicrobial Agents and Chemotherapy, 2007
- Carbapenemases: the Versatile β-LactamasesClinical Microbiology Reviews, 2007
- Multicopy bla OXA-58 Gene as a Source of High-Level Resistance to Carbapenems in Acinetobacter baumanniiAntimicrobial Agents and Chemotherapy, 2007
- Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumanniiAntimicrobial Agents and Chemotherapy, 2007
- High tigecycline resistance in multidrug-resistant Acinetobacter baumannii—authors' responseJournal of Antimicrobial Chemotherapy, 2007
- In Vitro Activities of Various Antimicrobials Alone and in Combination with Tigecycline against Carbapenem-Intermediate or -Resistant Acinetobacter baumanniiAntimicrobial Agents and Chemotherapy, 2007
- Horizontal Gene Transfer in a Polyclonal Outbreak of Carbapenem-ResistantAcinetobacter baumanniiJournal of Clinical Microbiology, 2007
- Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumanniiAntimicrobial Agents and Chemotherapy, 2006
- First Report of the Carbapenem-Hydrolyzing Oxacillinase OXA-58 in Acinetobacter baumannii Isolates in ItalyAntimicrobial Agents and Chemotherapy, 2006
- Metallo-β-Lactamases: the Quiet before the Storm?Clinical Microbiology Reviews, 2005